drugset
Drugs / AVP-786
last change May 2024 re-read 2 minutes ago

AVP-786

also known as Deuterated Dextromethorphan
Developed for
neurodevelopmental disorder · schizophrenia · impulse control disorder
Investigated by
Otsuka Pharmaceutical Development & Commercialization, Inc.

Trials 7 · a red edge is where a trial was stopped

today NCT03095066 · Ph 2 NCT02477670 · Ph 2 NCT02402595 · Ph 1 NCT02336347 · Ph 1 NCT02174822 · Ph 1 NCT02174835 · Ph 1 NCT01787747 · Ph 1
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT02402595 Mar → Jul 2015 — Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Phase 1 NCT02336347 May → Sep 2014 — Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Phase 1 NCT02174822 Jan → Mar 2014 — Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Phase 1 NCT02174835 Sep → Nov 2013 — Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Phase 1 NCT01787747 Oct 2012 → Feb 2013 — Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Phase 22 trials
Phase 2 NCT03095066 May 2017 → Aug 2022 neurodevelopmental disorder Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Phase 2 NCT02477670 Sep 2015 → Jul 2017 schizophrenia Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02534038 Comparator Dec 2015 → Oct 2017 impulse control disorder Otsuka Pharmaceutical Development & Commercialization, Inc. Terminated No outcome recorded

Press releases naming this drug 8 releases

DateIssuerRelease
2024-05-22 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka to Terminate Development of AVP-786 otsuka.co.jp ↗
2024-05-22 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka to Terminate Development of AVP-786 otsuka-us.com ↗
2024-02-13 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease otsuka.co.jp ↗
2024-02-12 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated With Dementia Due to Alzheimer’s Disease otsuka-us.com ↗
2019-11-12 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka Pharmaceutical and Avanir Pharmaceuticals to Continue Clinical Development ofInvestigational AVP-786 for the Treatment of Agitation in Patients with Alzheimer's Dementia otsuka.co.jp ↗
2019-09-27 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka's Subsidiary Avanir Pharmaceuticals Reports Top-line Data from Second Phase 3 Trial Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia otsuka.co.jp ↗
2019-03-25 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka's Subsidiary Avanir Pharmaceuticals Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia otsuka.co.jp ↗
2015-11-17 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka Pharmaceutical Affiliate Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer's Disease otsuka.co.jp ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as AVP-786 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02534038 ↗
7

NCT02336347 ↗

NCT02174835 ↗

NCT02174822 ↗

NCT01787747 ↗

NCT03095066 ↗

NCT02477670 ↗

NCT02402595 ↗
Known as Deuterated Dextromethorphan “AVP-786 (Deuterated Dextromethorphan)” NCT01787747 ↗
Route Oral “AVP-786 twice daily orally for Days 13 - 20.” NCT02174822 ↗